Genflow Biosciences Plc · LSE:GENF
Genflow Biosciences — Investor Presentation (July 2026)
20 slides from Genflow Biosciences's investor presentation, July 2026
Slide 1: Corporate Overview
CORPORATE OVERVIEW July 2026 gb LSE: GENF - OTCQB: GENFF
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts. Certain information and statements include financial project
Slide 3: Who We Are
WHO WE ARE Pioneering Novel Gene Therapies for a Longer Healthier Life MISSION PROPRIETARY SIRT6c GENE We develop gene therapies that target aging at its Centenarian SIRT6 (SIRT6c) source—slowing or halting the process in humans and Proprietary variant found in long-lived dogs. By tackling aging, th
Slide 4: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DR. VERA DR. ERIC VERDIN DR. MATTHEW DR. MANLIO PROF. DR. SVEN DR. MARY GORBUNOVA, PHD MD/PHD HIRSCHEY, PHD VINCIGUERRA, PHD FRANCQUE, PHD RINELLA, MD CO Director CEO & President Assistant Professor Principle Investigator NASH Expert NASH Expert Rochester Aging Buck Institu
Slide 5: Management
MANAGEMENT GAD BERDUGO, MSc Eng., MBA DR ERIC LEIRE MD MBA Chairperson Founder & CEO • 35+ years of leadership across global biotech • MD and MBA, Eric has been involved in business & corporate development, venture biotech for over 30 years management and U.S. capital markets with a • Research posit
Slide 6: Gene Regulation in Aging (SIRT6)
GENE REGULATION IN AGING Aging is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage GENOME MANY GENES REGULATE AGING. INSTABILITY OUR FOCUS IS THE CENTENARIAN SIRT6 ALTERED INTRA CELLULAR TELOMERE (SIRT6c) GENE COMMUNICATION ATTRITION Aging is driven by int
Slide 7: Why Centenarian SIRT6 (SIRT6c)
WHY CENTENARIAN SIRT6 (SIRTc) • Master regulator of DNA repair, metabolism, inflammation, aging • Centenarian SIRT6 variant (SIRT6c) with enhanced activity • Broad relevance across liver, retina, muscle and systemic aging SIRT6 Lifespan Lifespan 5 different DSB repair DSB repair amino acids between
Slide 8: SIRT6c Edge: Centenarian Genetics Validated Benefit
SIRT6c EDGE:CENTENARIAN GENETICS VALIDATED BENEFIT • Sirtuins are a family of highly conserved signaling proteins involved in metabolic regulation and implicated in influencing cellular processes incl. aging • Sirtuin 6 is a stress responsive NAD+- dependent histone deacetylase (HDAC) promoting incr
Slide 9: Development Pipeline
DEVELOPMENT PIPELINE SIRT6c Gene Therapies Platform • Priority Programs PROGRAM PRE-CLINICAL IND-ENABLING PHASE I/II PHASE II/III Anti-Aging Dogs ✓ ✓ ONGOING GF-1004 — Naked DNA • SIRT6c Clinical POC Planned COMPLETED COMPLETED Veterinary Partner Readout Q1 2026 MASH ONGOING ONGOING GF-1002 ● ONGOIN
Slide 10: Rationale for SIRT6 Use to Extend Lifespan
RATIONALE FOR SIRT6 USE TO EXTEND LIFESPAN SIRT6 transgenic mice SIRT6 knockout (KO) SIRT6 Overexpression (OE) sexes pooled 125 100 sur vival 75 50 SIRT6-KO WT SIRT1 SIRT6-Het SIRT6 25 SIRT1+6 SIRT6-WT 0 0 5 10 15 20 25 30 days Cell. 2006 Jan 27;124(2):315-29. LSE: GENF - OTCQB: GENFF 10
Slide 11: Rationale for SIRT6 Use to Extend Lifespan
RATIONALE FOR SIRT6 USE TO EXTEND LIFESPAN SIRT6 OE in aged cells reverses epigenetic age (DNA mAge) ✱ ✱ a b 55 DNA methylation age 50 DNA methylation age 50 45 40 40 35 30 30 T6 ol Control SIRT6 tr R on SI C LSE: GENF - OTCQB: GENFF 11
Slide 12: Rationale for SIRT6c Use in Sarcopenia
RATIONALE FOR SIRT6c USE IN SARCOPENIA Genflow SIRT6c study conducted with Rochester University, NY Frailty Test in Mice SIRT6c demonstrates statistically significant improvement 18-month-old male mice LSE: GENF - OTCQB: GENFF 12
Slide 13: Aged Dogs Comparative Trial (SLAB)
AGED DOGS COMPARATIVE TRIAL (SLAB) Proof-of-Concept: in-vivo randomized blinded naked DNA gene therapy in aged beagles TRIAL DESIGN TREATMENT GROUPS (n=6 per group) CRO: Syngene (GLP-certified facility) Group 1 Untreated control Animals: 25 aged Beagles; age > 10 years Group 2 IV bolus — AAV8 SIRT6c
Slide 14: Naked DNA Delivery for Dogs
NAKED DNA DELIVERY FOR DOGS Naked DNA in vivo delivery in small mammals like dogs holds several advantages: Safety and Simplicity: Naked DNA lacks viral components, reducing the risk of immune responses and integration-related mutagenesis, making it safer than viral vectors. Cost-Effectiveness: Unli
Slide 15: Glaucoma RGC Neuroprotection: The Race Is On
GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON Significant Market Opportunity 80M people worldwide with glaucoma Leading cause of irreversible blindness The Problem: unmet need for neuroprotection Current treatments: only lower intra-ocular pression (IOP), don't protect retinal ganglion cells (RGCs) R
Slide 16: Partnering with LNP Providers
PARTNERING WITH LNP PROVIDERS Paradigm shift to retinal protection • Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma / optic neuropathy models • Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Intravitreal (IVT) delivery is now tr
Slide 17: Advanced MASH Program
ADVANCED MASH PROGRAM SIRT6cent Validated Benefits • Affects est. 35 million people globally ⦁ Enhanced DNA repair capacity and genomic stability ⦁ HCC prevention: ⦁ Anti-fibrotic effects: reduced Col1A1 deposition and modulation of ECM- Increasing prevalence hepatocyte stiffness related genes, redu
Slide 18: Value Inflection Points Timeline
VALUE INFLECTION POINTS TIMELINE Upcoming catalysts expected to drive significant value creation in 2026–27 Q1 2026 Q2 2026 2026-2027 Aged Dog Trial Interim Aged Dog Trial MASH IND-Enabling → Readout completion IND-Ready Dog-specific epigenetic age clock + Licensing out or trade sale of 24 months to
Slide 19: Summary
SUMMARY LARGE & EXPANDING MARKETS GROWING IP PORTFOLIO • Advanced MASH: High unmet needs, rising prevalence • Two proprietary patent families: SIRT6c & gene delivery • Dog anti-aging and sarcopenia indications • Both patent families entering National Phase in 5 • Ophthalmology: 80M people with glauc
Slide 20: Thank You
THANK YOU contacts CEO, GENFLOW BIOSCIENCES Dr. Eric Leire: +32 477 495 881 HARBOR ACCESS INVESTOR RELATIONS Jonathan Paterson: +1 475 477 9401 Matt Kelly +1 475 477 9404 GENFLOW BIOSCIENCES SRL Biopark Gosselies Clement Ader 10 6041 Gosselies, Belgium GENFLOW BIOSCIENCES Plc 6 Heddon Street London
Genflow Biosciences — Investor Presentation (July 2026) on 6ix